




RESEARCH REPORT



OTC/DTC INFECTIOUS DISEASE DIAGNOSTICS

Strategies and Trends for Over the Counter and Direct To Consumer. Forecasts by Application by Channel by Country. With Market Analysis, Executive Guides, Customization and Market Opportunity Analysis

2022 to 2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1 Market Guides21

1.1 Situation Analysis 22

1.2 Guide for Executives and Marketing Staff 24

1.3 Guide for Investment Analysts and Management Consultants..... 25

2 Introduction and Market Definition26

2.1 What is OTC and DTC Testing?..... 27

2.2 OTC/DTC Testing – the quiet revolution in diagnostics 28

2.3 Self vs. Send – who knew? 29

2.4 Market Definition 30

2.4.1 Retail vs. Wholesale 30

2.4.2 OTC, DTC, HxV and HSG 30

2.4.3 Currency 31

2.4.4 Years 31

2.5 Methodology..... 32

2.5.1 Methodology 32

2.5.2 Sources 32

2.5.3 Authors 32

2.6 Perspective: Healthcare and the IVD Industry 34

2.6.1 Global Healthcare Spending 34

2.6.2 Spending on Diagnostics 35

2.6.3 Important Role of Insurance for Diagnostics 37

3 The Infectious Diseases – Guide to the Pathogens.....38

3.1 HIV - Human Immunodeficiency Virus (AIDS) 39

- 3.1.1 Virology 39
 - 3.1.1.1 Classification 39
 - 3.1.1.2 Structure and genome..... 40
 - 3.1.1.3 Tropism..... 42
 - 3.1.1.4 Replication cycle..... 45
 - 3.1.1.5 Genetic variability 50
- 3.1.2 Diagnosis 52
- 3.1.3 Testing..... 53
 - 3.1.3.1 Antibody tests 53
 - 3.1.3.2 Point of Care Tests (POCT) 56
 - 3.1.3.3 Antigen Tests 59
 - 3.1.3.4 Nucleic acid-based tests (NAT) 59
 - 3.1.3.5 Other tests used in HIV treatment..... 60
- 3.2 HBV – Hepatitis B..... 62
 - 3.2.1 Virology 63
 - 3.2.1.1 Genome 64
 - 3.2.1.2 Pathogenesis..... 65
 - 3.2.1.3 Hepatitis B virus replication 65
 - 3.2.1.4 Serotypes and genotypes..... 66
 - 3.2.2 Mechanisms..... 66
 - 3.2.3 Diagnosis 67
 - 3.2.4 Market Opportunity Analysis 68
- 3.3 HCV – Hepatitis C..... 69
 - 3.3.1 Taxonomy..... 70
 - 3.3.1.1 Structure 70
 - 3.3.1.2 Genome 71

- 3.3.2 Molecular biology 72
- 3.3.3 Replication 73
- 3.3.4 Genotypes 75
 - 3.3.4.1 Clinical importance 75
- 3.3.5 Market Opportunity Analysis 76
- 3.4 HPV - Human papillomavirus 77
 - 3.4.1 Virology 79
 - 3.4.1.1 E6/E7 proteins 79
 - 3.4.1.2 Role in cancer 79
 - 3.4.1.3 Research 80
 - 3.4.1.4 Latency period 81
 - 3.4.1.5 Clearance 81
 - 3.4.2 Diagnosis 82
 - 3.4.2.1 Cervical testing 82
 - 3.4.2.2 Oral testing 84
 - 3.4.2.3 Testing men 84
 - 3.4.2.4 Other testing 85
 - 3.4.3 Market Opportunity Analysis 86
- 3.5 Coronavirus 93
 - 3.5.1 Severe acute respiratory syndrome (SARS) 95
 - 3.5.2 Middle East respiratory syndrome (MERS) 96
 - 3.5.2 COVID-19. The SARS CoV 2 Virus 98
 - 3.5.2.1 Signs and symptoms 99
 - 3.5.2.2 Transmission 100
 - 3.5.2.3 Diagnosis 101
 - 3.5.2.4 Prevention 103

- 3.5.2.5 Management..... 104
- 3.5.2.6 Prognosis..... 105
- 3.5.3 Pandemic Diagnostics 106
 - 3.5.3.1 Risk Management – Spark and Spread 106
 - 3.5.3.2 Dx Technology – Nucleic Acid Based 108
 - 3.5.3.3 Dx Technology - Immunoassay..... 108
 - 3.5.3.4 Time to Market and Preparedness Issues..... 109
- 3.6 Influenza..... 109
 - 3.6.1 Flu..... 111
 - 3.6.1.1 Types of virus 111
 - 3.6.1.2 Influenzavirus A 111
 - 3.6.1.3 Influenzavirus B 112
 - 3.6.1.4 Influenzavirus C 112
 - 3.6.1.5 Structure, properties, and subtype nomenclature 112
 - 3.6.1.6 Replication 114
 - 3.6.2 Testing..... 116
 - 3.6.2.1 Advantages/Disadvantages of Molecular Assays..... 118
 - 3.6.3 Market Opportunity Analysis 119
- 3.7 CT/NG - Chlamydia/Gonorhea 128
 - 3.7.1 Gonorrhea 128
 - 3.7.1.1 Diagnosis 129
 - 3.7.1.2 Screening 129
 - 3.7.2 Chlamydia 129
 - 3.7.2.1 Diagnosis 130
 - 3.7.2.2 Screening 131
 - 3.7.3 Testing..... 132

- 3.7.3.1 Nucleic acid amplification tests (NAATs)..... 132
- 3.7.3.2 Performance of NAAT Tests..... 141
- 3.7.4 Market Opportunity Analysis 142
- 3.8 UTI 144
 - 3.8.1 Diagnosis 144
 - 3.8.2 Testing..... 146
 - 3.8.2.1 Nitrites test 146
 - 3.8.2.2 Leukocytes test 147
 - 3.8.3 Market Opportunity Analysis 148
- 3.9 GAS 149
 - 3.9.1 Infectious Agents..... 149
 - 3.9.2 Market Opportunity Analysis 151
- 3.10 RESP 152
 - 3.10.1 Diagnosis 153
 - 3.10.2 Market Opportunity Analysis 154
- 4 Industry Overview.....156
 - 4.1 Industry Participants 157
 - 4.1.1 IVD Supplier..... 157
 - 4.1.2 Independent lab specialized/esoteric 158
 - 4.1.3 Independent lab national/regional..... 158
 - 4.1.4 Independent lab analytical 159
 - 4.1.5 Public National/regional lab 159
 - 4.1.6 Hospital lab 159
 - 4.1.7 Physician lab..... 160
 - 4.1.8 Pharmacies 160
 - 4.1.9 Audit body 161

- 4.2 The Clinical Laboratory Market Segments 162
 - 4.2.1 Traditional Market Segmentation..... 162
 - 4.2.2 Laboratory Focus and Segmentation..... 163
 - 4.2.3 Segmenting the OTC/DTC Market 164
- 4.3 Industry Structure..... 166
 - 4.3.1 Hospital Testing Share 166
 - 4.3.2 Economies of Scale..... 166
 - 4.3.3 Hospital vs. Central Lab 167
 - 4.3.4 Physician Office Lab's..... 168
 - 4.3.4.1 The Problem with POLS..... 168
 - 4.3.5 Physician's and OCT/DTC 169
 - 4.3.6 Pharmacies and OCT/DTC 169
 - 4.3.6.1 The Diagnostic Plight of Pharmacies – Trying to do good..... 169
 - 4.3.6.2 The Theranos Legacy 170
- 5 Market Trends 171
 - 5.1 Factors Driving Growth 172
 - 5.1.1 Privacy and Anonymity..... 172
 - 5.1.2 The Internet Effect 172
 - 5.1.3 Rapid Result 173
 - 5.1.4 The Wellness Movement 173
 - 5.1.5 The COVID-19 Impact..... 173
 - 5.2 Factors Limiting Growth 174
 - 5.2.1 Trust Factor..... 174
 - 5.2.2 Infectious Disease is Declining But..... 176
 - 5.2.3 Wellness Hurts..... 176
 - 5.2.4 Economic Growth improves Living Standards 176

- 5.3 Diagnostic Technology Development 177
 - 5.3.1 The Multiplex Paradigm Shift..... 177
 - 5.3.2 NAT vs. Lateral Flow 179
 - 5.3.3 The Unusual Role of GPS 179
 - 5.3.4 Self and Send Competition 179
 - 5.3.5 The Relationship to DTC Genetic 180
 - 5.3.6 The Relationship to TeleHealth 181
 - 5.3.7 Sample Collection – Who Knew?..... 181
- 6 OTC/DTC Infectious Disease Testing Recent Developments..... 182
 - 6.1 Recent Developments – Importance and How to Use This Section 183
 - 6.1.1 Importance of These Developments 183
 - 6.1.2 How to Use This Section..... 183
 - 6.2 Startup Detect to Roll Out Next-Gen Molecular Instrument 183
 - 6.3 Diagnostics for the Real World Third-Generation POC Platform 186
 - 6.4 Labcorp Partnering With Getlabs for Home Collection..... 189
 - 6.5 Salignostics Closes Funding Round..... 190
 - 6.6 Cue Health Targets DTC Market in 2022..... 191
 - 6.7 Grip Molecular Developing Home Respiratory Panel..... 194
 - 6.8 Mainz Biomed Developing Home ColoAlert Assay 198
 - 6.9 MFB Fertility Closes Series A Financing Round..... 202
 - 6.10 Continued Demand for SARS-CoV-2 Rapid Tests 202
 - 6.11 Rapid Covid-19 Test Results Risk Going Uncounted 204
 - 6.12 FDA Grants EUAs for Direct-to-Consumer Coronavirus Kit 206
 - 6.13 Researchers Develop 15-Minute PCR System 207
 - 6.14 Stanford Developing Low-Cost, At-Home, COVID-19 Saliva Test..... 209
 - 6.15 Lucira Health Files for \$115M IPO 213

6.16 Spectrum Solutions Gets CE Mark for Saliva Collection Devices 214

6.17 Sherlock Biosciences Receives Gates Foundation Grant for COVID-19 Self-Test 215

6.18 LabCorp Receives EUA for OTC COVID-19 Test Home Collection Kit 216

6.19 FemtoDx Launches Rapid At-Home Test Development for COVID-19 217

6.20 FDA approves first at-home coronavirus test 218

6.21 Free Home HIV Tests Detect More Infections 218

6.22 Biohacking trend supports self testing. 219

6.23 PerkinElmer and EverlyWell to Expand U.S. At-Home Health Test Market 221

6.24 Mylan, Atomo Diagnostics Get WHO Prequalification Approval for HIV Self-Test ... 222

6.25 OraSure Technologies, Inc. Announces Two Acquisitions..... 223

6.26 Nigerian Govt Approves Alere HIV Self-Test Kit 226

6.27 Boots launches UTI test and treat service across 37 branches 227

6.28 Scanwell Health moves beyond home UTI testing 228

6.29 Healthy.io raises \$18 million for at-home urinalysis tests 229

6.30 LetsGetChecked collects \$30M more for at-home health testing 231

6.31 TestCard, a \$4 Urine Test Read by Smartphone 232

6.32 Digital Health Startup EverlyWell Raises \$50M..... 233

6.33 Thriva adds test-at-home kits for female hormone and cortisol stress 235

6.34 Tasso scores \$6.1M for patch-based home blood testing 237

6.35 DBS Systems HEMAXIS receives CE/IVD mark..... 238

6.36 Abbott HbA1c point-of-care test reliably diagnoses diabetes 239

7 Profiles of Key Diagnostic Testing Companies241

7.1 1DropDiagnostics 242

7.2 Abbott Laboratories..... 243

7.3 Ador Diagnostics 245

7.4 ADT Biotech 246

7.5 Akonni Biosystems 247

7.6 Alveo Technologies..... 248

7.7 Antelope Dx..... 249

7.8 Applied BioCode 250

7.9 Atomo Diagnostics..... 252

7.10 Aus Diagnostics 253

7.11 Becton, Dickinson and Company 254

7.12 Binx Health 256

7.13 Biocartis..... 258

7.14 BioFire Diagnostics (bioMérieux) 259

7.15 bioMérieux Diagnostics..... 261

7.16 Bio-Rad Laboratories, Inc..... 263

7.17 Bosch Healthcare Solutions GmbH..... 265

7.18 Cepheid (Danaher) 266

7.19 Cue Health..... 268

7.20 Curetis N.V. / Curetis GmbH..... 270

7.21 DBS Systems 271

7.22 Detect 272

7.23 Diagenode Diagnostics 273

7.24 Diasorin S.p.A..... 274

7.25 Ellume 276

7.26 Everywell 277

7.27 Getlabs..... 278

7.28 Grip Molecular Technologies 279

7.29 Healthy.io 280

7.30 Hologic 281

7.31 Inflammatrix 283

7.32 Invetech..... 284

7.33 Janssen Diagnostics 285

7.34 Karius 286

7.35 Laboratory Corporation of America..... 287

7.36 Letsgetchecked 289

7.37 Lexogene 290

7.38 Lucira Health..... 291

7.39 Luminex Corp 292

7.40 Mbio Diagnostics..... 294

7.41 Mesa Biotech (Thermo Fisher) 295

7.42 MFB Fertility..... 296

7.43 Mobidiag (Hologic) 297

7.44 myLabBox 298

7.45 Mylan..... 299

7.46 Nanomix..... 300

7.47 OraSure Technologies..... 301

7.48 Oxford Nanopore Technologies 302

7.49 Panagene..... 303

7.50 Primerdesign (Novacyt) 304

7.51 Prominex 305

7.52 Qiagen..... 306

7.53 QuantuMDx 308

7.54 Quest Diagnostics 309

7.55 Quidel..... 310

7.56 Randox Toxicology..... 312

7.57 Roche Molecular Diagnostics 313

7.58 Salignostics..... 315

7.59 Scanwell Health..... 316

7.60 SD Biosensor 317

7.61 Seegene..... 318

7.62 Seventh Sense Biosystems..... 319

7.63 Siemens Healthineers 320

7.64 T2 Biosystems..... 322

7.65 TestCard 323

7.66 Thermo Fisher Scientific Inc..... 324

7.67 Thriva 326

7.68 Visby Medical 327

7.69 XCR Diagnostics 329

8 Global Market Size330

8.1 OTC/DTC ID Global Market Size by Country 331

8.1.1 OTC/DTC ID Global Market Size by Country Table 331

8.1.2 OTC/DTC ID Global Market Size by Country Chart 332

8.2 OTC/DTC ID Global Market Size by Syndrome 333

8.2.1 OTC/DTC ID Global Market Size by Syndrome Table 333

8.2.2 OTC/DTC ID Global Market Size by Syndrome Share by Year..... 334

8.2.3 OTC/DTC ID Global Market Size by Syndrome Base vs Final..... 335

8.2.4 OTC/DTC ID Global Market Size by Syndrome Base Year..... 336

8.2.5 OTC/DTC ID Global Market Size by Syndrome Final Year 337

8.2.6 OTC/DTC ID Global Market Size by Syndrome Segment Growth..... 338

8.3 OTC/DTC ID Global Market Size by Channel..... 339

8.3.1 OTC/DTC ID Global Market Size by Channel Table..... 339

- 8.3.2 OTC/DTC ID Global Market Size by Channel Share by Year 340
- 8.3.3 OTC/DTC ID Global Market Size by Channel Base vs Final 341
- 8.3.4 OTC/DTC ID Global Market Size by Channel Base Year 342
- 8.3.5 OTC/DTC ID Global Market Size by Channel Final Year..... 343
- 8.3.6 OTC/DTC ID Global Market Size by Channel Segment Growth 344
- 9 Global Market by Syndrome345
 - 9.1 Respiratory Market 346
 - 9.1.1 Respiratory Market by Country Table 346
 - 9.1.2 Respiratory Market Chart..... 347
 - 9.2 STD Market 348
 - 9.2.1 STD Market by Country Table 348
 - 9.2.2 STD Market Chart..... 349
 - 9.3 UTI Market 350
 - 9.3.1 UTI Market by Country Table 350
 - 9.3.2 UTI Market Chart 351
 - 9.4 HxV Market 352
 - 9.4.1 HxV Market by Country Table 352
 - 9.4.2 HxV Market by Chart..... 353
 - 9.5 Other Market 354
 - 9.5.1 Other Market by Country Table 354
 - 9.5.2 Other Market Chart..... 355
- 10 Global Market by Channel356
 - 10.1 OTC Market..... 357
 - 10.1.1 OTC Market by Country Table..... 357
 - 10.1.2 OTC Market Chart 358
 - 10.2 DTC Market 359

- 10.2.1 DTC Market by Country Table 359
- 10.2.2 DTC Market Chart..... 360
- 10.3 HSG Market..... 361
 - 10.3.1 HSG Market by Country Table..... 361
 - 10.3.2 HSG Market Chart 362
- 11 Appendices363
 - 11.1 United States Medicare System: 2022 Clinical Laboratory Fees Schedule..... 363
 - 11.2 FDA Approved Microbial Tests 457

Table of Tables

Table 1 Classification of HIV Species..... 40

Table 2 HBV Tests - CMS Codes & Prices 69

Table 3 HCV Tests - CMS Codes & Prices 76

Table 4 HPV Clearance Rates 82

Table 5 HPV Tests - CMS Codes & Prices..... 87

Table 6 HPV Tests, Technology, Types 88

Table 7 Characteristics of Coronavirus Pandemic Infections 98

Table 8 COVID-19 Symptoms..... 100

Table 9 Types of Influenza Tests 116

Table 10 Influenza Tests - CMS Codes & Prices..... 119

Table 11 FDA Cleared Molecular Assays for Influenza 120

Table 12 FDA Cleared NAAT CTGC Tests 134

Table 13 CTGC NAAT Target Sequences and Possible False Reactions 139

Table 14 CT/NG Tests - CMS Codes & Prices 143

Table 15 GAS Panel BioFire 151

Table 16 BioFire RESP Panel..... 154

Table 17 Market Players by Type 157

Table 18 Clinical Laboratory Departments and Segments 162

Table 19 Laboratory Management Focus – Different Approaches 163

Table 20 Key Segmentation Variables Going Forward..... 164

Table 21 Possible Market Segments of OTC/DTC Market..... 164

Table 22 Five Factors Driving Growth 172

Table 23 Four Factors Limiting Growth 174

Table 24 Self vs. Send TAT..... 180

Table 25 OTC/DTC ID Global Market by Country/Region..... 331

Table 26 OTC/DTC ID Global Market by Syndrome..... 333

Table 27 OTC/DTC ID Global Market by Channel 339

Table 28 Respiratory Syndrome by Country 346

Table 29 STD Testing market by country 348

Table 30 UTI Testing market by country..... 350

Table 31 HxV Testing market by country..... 352

Table 32 Other Testing market by country..... 354

Table 33 OTC Market by Country 357

Table 34 DTC market by country 359

Table 35 HSG market by country..... 361

Table 36 2022 Clinical Lab Fee Schedule 363

Table of Figures

Figure 1 Global Healthcare Spending Map 35

Figure 2 The Lab Test Pie 36

Figure 3 HIV Virion 41

Figure 4 Diagram of the HIV Replication Cycle 45

Figure 5 The Structure of the HBV Virus..... 64

Figure 6 Hepatitis B Replication 65

Figure 7 Structure of the HCV Virus..... 71

Figure 8 HCV Replication Cycle 74

FIGURE 9 STRUCTURE OF CORONAVIRUSES 94

Figure 10 Structure of the Influenza Virion 113

Figure 11 Influenza Replication..... 114

Figure 12 Chart Death Rates and Infectious Disease Decline 175

Figure 13 The Multiplex Paradigm Shift..... 178

Figure 14 Market Size by Country - Key Countries..... 332

Figure 15 Chart of Global Market by Syndrome by Year 334

Figure 16 Syndrome Segment Shares Base vs Final..... 335

Figure 17 Syndrome Share Base Year..... 336

Figure 18 Syndrome Share Final Year 337

Figure 19 Syndrome Segment Growth Rates..... 338

Figure 20 Chart of Global Market by Channel by Year..... 340

Figure 21 Channel Segment Shares Base vs Final 341

Figure 22 Channel Share Base Year 342

Figure 23 Channel Share Final Year 343

Figure 24 Channel Segment Growth Rates 344

Figure 25 Chart - Respiratory market Growth 347

Figure 26 Chart – STD market Growth 349

Figure 27 Chart – UTI market Growth..... 351

Figure 28 Chart - HxV market Growth 353

Figure 29 Chart – Other market Growth 355

Figure 30 Chart - OTC market Growth 358

Figure 31 Chart – DTC market Growth 360

Figure 32 Chart – HSG market Growth..... 362